scholarly journals Stimulation of monocyte tissue factor expression in an in vitro model of bacterial endocarditis.

1994 ◽  
Vol 62 (12) ◽  
pp. 5669-5672 ◽  
Author(s):  
M J Bancsi ◽  
J Thompson ◽  
R M Bertina
2012 ◽  
Vol 129 ◽  
pp. S170
Author(s):  
E. Napoleone ◽  
A. Cutrone ◽  
D. Cugino ◽  
R. Tambaro ◽  
A. De Curtis ◽  
...  

Nutrition ◽  
2011 ◽  
Vol 27 (9) ◽  
pp. 967-972 ◽  
Author(s):  
Cecilia M. Shing ◽  
Murray J. Adams ◽  
Robert G. Fassett ◽  
Jeff S. Coombes

1999 ◽  
Vol 60 (7) ◽  
pp. 598-607 ◽  
Author(s):  
A El Ghalbzouri ◽  
B Drénou ◽  
V Blancheteau ◽  
C Choqueux ◽  
R Fauchet ◽  
...  

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 2215-2215 ◽  
Author(s):  
Teena Rehani ◽  
Kristin Mathson ◽  
John D Belcher ◽  
Gregory M Vercellotti ◽  
Arne Slungaard

Abstract Intravascular hemolytic diseases such as sickle cell anemia as well as diseases such as sepsis/DIC in which intravascular hemolysis occurs are frequently complicated by micro- and macrovascular thrombosis but mechanisms underlying this association are unclear. Plasma heme levels in sickle cell anemia are typically 5-30 µM. LPS is a prototypic and potent agonist for peripheral blood monocyte tissue factor expression and by this mechanism contributes to thrombosis in sepsis. Because heme, like LPS, signals by binding to and activating TLR4, we hypothesized that heme would also stimulate tissue factor expression in monocytes and so promote thrombosis in sickle cell anemia. We isolated human peripheral blood mononuclear cells (PBMC) and monocytes, incubated them 4 hours in the presence or absence of 10 µM hemin or 10 ng/ml LPS, made whole cell lysates by freeze-thawing and sonication and measured tissue factor activity using a one-stage clotting assay employing recalcified citrated human plasma. The assay was standardized with recombinant human tissue factor and the tissue factor dependence of the assay was confirmed using the neutralizing anti-human tissue factor antibody ATF. Hemin stimulated PBMC TF activity ca. 40-fold (range 6- to 296-fold) from 53 to 1885 pg/ml/million cells, an extent comparable to that of LPS (1939 pg/ml/million cells). In isolated monocytes heme increased TF activity ca. 70-fold (range 25-115-fold) to 9800 pg/ml/million cells, again comparable to LPS (8500 pg/ml/million cells.) Heme stimulation of monocyte TF expression did not reflect endotoxin contamination of our hemin preparation because it was 1) reproduced with a preparation of hemin made for infusion into patients with intermittent porphyria that had no detectable endotoxin; 2) unaffected by addition of 1 µg polymyxin B, which abrogated LPS stimulation; 3) blocked by 15 µM hemopexin, a high affinity heme-binding protein. qRT-PCR of TF expression in monocytes shows a 140-350-fold increase in TF mRNA levels over baseline between 2 and 4 hours after exposure to heme. Examining pathways for heme signaling, we demonstrate that heme stimulation of TF expression in monocytes is impaired > 90% by inhibitors of TLR4 (TAK242), NADPH oxidase (diphenylene iodonium), PKC (5 µM calphostin) and ERK ½ (10 µM U-0126), impaired 75% by the p50 NF-kB inhibitor 10 µg/ml andrographolide and unaffected by 100 nM wortmannin, an AKT/PI3K pathway inhibitor. We conclude that heme, at concentrations found in intravascular hemolytic diseases such as sickle cell anemia, is a highly potent stimulant of blood monocyte TF transcriptional expression dependent upon signaling through TLR4, PKC, NADPH oxidase, ERK ½ and NF-kB. By this direct mechanism heme may promote thrombosis and contribute to the pathogenesis of sickle cell anemia and other diseases characterized by intravascular hemolysis, including sepsis/DIC. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2013 ◽  
Vol 121 (4) ◽  
pp. 692-699 ◽  
Author(s):  
Richard S. Robins ◽  
Catherine A. Lemarié ◽  
Sandrine Laurance ◽  
Meghedi N. Aghourian ◽  
Jianqiu Wu ◽  
...  

Abstract Gas6 (growth-arrest specific gene 6) plays a role in thrombus stabilization. Gas6 null (−/−) mice are protected from lethal venous and arterial thromboembolism through platelet signaling defects induced only by 5μM ADP and 10μM of the thromboxane analog, U46619. This subtle platelet defect, despite a dramatic clinical phenotype, raises the possibility that Gas6 from a source other than platelets contributes to thrombus formation. Thus, we hypothesize that Gas6 derived from the vascular wall plays a role in venous thrombus formation. Bone marrow transplantation and platelet depletion/reconstitution experiments generating mice with selective ablations of Gas6 from either the hematopoietic or nonhematopoietic compartments demonstrate an approximately equal contribution by Gas6 from both compartments to thrombus formation. Tissue factor expression was significantly reduced in the vascular wall of Gas6−/− mice compared with WT. In vitro, thrombin-induced tissue factor expression was reduced in Gas6−/− endothelial cells compared with wild-type endothelium. Taken together, these results demonstrate that vascular Gas6 contributes to thrombus formation in vivo and can be explained by the ability of Gas6 to promote tissue factor expression and activity. These findings support the notion that vascular wall-derived Gas6 may play a pathophysiologic role in venous thromboembolism.


PLoS ONE ◽  
2012 ◽  
Vol 7 (3) ◽  
pp. e33203 ◽  
Author(s):  
Nataša Nikolić ◽  
Siril Skaret Bakke ◽  
Eili Tranheim Kase ◽  
Ida Rudberg ◽  
Ingeborg Flo Halle ◽  
...  

1987 ◽  
Author(s):  
J B Hansen ◽  
J O Olsen ◽  
L Wilagård ◽  
B Østerud

In an in vitro model, stimulation of blood cells with a low concentration of lipopolysaccharides (LPS) revealed differences between women and men that possibly could be an explanation to why young women have less coronary heart disease than men (see abstract Hansen et al. “A model to--”).This model was also used to study the effect of intake of cod liver oil (CLO). 40 students (20 men and 20 women) were tested followed by an intake of 25 ml CLO daily for 2 months by 20 of the students.Heparinized blood samples were incubated with 2 ng LPS/ ml for 2 hours followed by isolation of plasma for thromboxane B2 and 6-keto-PG 1α quantitation.After the first 2 months period of CLO drinking we have the following results:The two months of CLO intake had no significant effect pn the thromboplastin induced synthesis in monocytes. In addition platelet aggregation was tested in a whole blood aggregometer using ADP addition to heparinized blood or collagen induced platelet aggregation in citrated whole blood. ADP aggregation was reduced from 75.9 ± 16.8% to 55.4 ± 19% in the CLO group of women, whereas the reduction in the CLO group of men was 70.1 ± 17.1% to 60.9±18.6%. Similar result were found with collagen aggregation (57% to 33% for women and 48% to 30% for men).It is concluded that CLO intake reduces TxA2 production and plateletaggregation without having reduced effect on PGI2 production in whole blood.


Sign in / Sign up

Export Citation Format

Share Document